In conclusion, our study provides evidence that H19 expression levels vary between different soft tissue sarcoma subtypes and provides unprecedented experimental evidence that H19 might be a valuable target for RNA‐targeting drugs to tackle H19 in soft tissue sarcomas. This evidence concerns the gene H19 and soft tissue sarcoma.